<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00789802</url>
  </required_header>
  <id_info>
    <org_study_id>07-1026</org_study_id>
    <nct_id>NCT00789802</nct_id>
  </id_info>
  <brief_title>A Randomized Controlled Trial of Oral Naproxen and Transdermal Estradiol for Bleeding in LNG-IUC</brief_title>
  <official_title>A Randomized, Controlled Trial of Oral Naproxen and Transdermal Estradiol for Prevention of Unscheduled Bleeding in New Users of Levonorgestrel Intrauterine Contraception</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American College of Obstetricians and Gynecologists</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize that the addition of oral naproxen or transdermal estradiol will decrease the
      number of days of unscheduled bleeding experienced by first-time users of the levonorgestrel
      intrauterine system (LNG-IUC) during the first 12 weeks of use compared to an oral placebo.
      The objective of this study is to compare the total number of days of bleeding experienced by
      first time users of the LNG-IUC randomized to oral naproxen or estradiol patch compared to
      those randomized to placebo for the first 12 weeks of use. We will enroll women initiating
      LNG-IUC to one of 3 groups, transdermal estrogen, oral naproxen or oral placebo. We will
      enroll a total of 114 women, 38 in each group. Women will keep bleeding diaries for 16 weeks
      which will be used to calculate the total number of bleeding or spotting days. Statistical
      analysis will be performed to evaluate if there is less bleeding among the treatment arms
      then the placebo arm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The levonorgestrel intrauterine system (LNG-IUC) is one of the most effective, reversible
      methods of contraception currently available in the United States. User satisfaction is
      overall high , however the most often cited reason for discontinuation is irregular bleeding
      . The LNG-IUC has mainly progesteronic effects on the uterine cavity. Morphological changes
      of the endometrium are observed, including stromal pseudo-decidualization and glandular
      atrophy . These endometrial changes may contribute to the irregular uterine bleeding
      experienced by women using the LNG-IUC. Up to 14% of women will discontinue the LNG-IUC
      within the 5-year period due to abnormal bleeding and up to 66% of woman who request removal
      of the LNG-IUC will do so in the first 6 months of use . Women may be less likely to
      discontinue the LNG-IUC due to abnormal bleeding patterns if they are counseled appropriately
      beforehand, however the prospect of irregular bleeding with few options for management may
      dissuade some women from even trying the LNG-IUC. A recent Cochrane review identified the
      need for further investigation into the treatment of irregular uterine bleeding caused by
      progestin only contraception .

      One treatment for progestin-induced irregular bleeding is the administration of nonsteroidal
      anti-inflammatory agents (NSAIDs). A 1999 study showed a significant decrease in the number
      of bleeding days in women using the levonorgestrel sub-dermal implant randomized to mefenamic
      acid 500 mg compared to placebo . A 2004 study found a 50% reduction in bleeding in depot
      medroxyprogesterone (DPMA) users randomized to mefenamic acid versus placebo . There have
      been no studies looking specifically at NSAIDs for the prevention or treatment of LNG-IUC
      related irregular bleeding. Naproxen is an antiprostaglandin that is commonly used in
      gynecological practice for relief of dysmenorrhea and has been used to treat menorrhagia. It
      is widely available, inexpensive, well-tolerated and has a low incidence of side effects.

      Previous studies have also shown the administration of estrogen alone and estrogen-containing
      oral contraceptives to users of subdermal levonorgestrel implants (NorplantÂ®) resulted in
      decreased frequency of irregular uterine bleeding , . A prior randomized, controlled trial
      found a 0.1mg estradiol patch resulted in the clinical improvement of abnormal bleeding,
      however this finding was not statistically significant . A randomized, controlled trial of
      DMPA users found the cyclic administration of 0.1mg estradiol patches did not decreases
      irregular menstrual bleeding . In this study, the cyclic use of estrogen may have resulted in
      lower or inconsistent serum estradiol levels. Additionally, the progestational mechanism of
      action is more similar between levonorgestrel subdermal implants and LNG-IUC than depot
      medroxyprogesterone. No study has specifically addressed estrogen for treatment of irregular
      bleeding with the LNG-IUC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Bleeding and Spotting Days</measure>
    <time_frame>12 weeks</time_frame>
    <description>The median number of bleeding and spotting days reported at 12 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Bleeding Days Observed in Women With a LNG-IUC Treated With Naproxen, Estradiol and Placebo.</measure>
    <time_frame>16 weeks</time_frame>
    <description>Median number of bleeding days observed in women with a LNG-IUC treated with naproxen, estradiol and placebo at 16 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction With the LNG-IUC at the End of the 12 Weeks Between the 3 Study Groups.</measure>
    <time_frame>12 weeks</time_frame>
    <description>To compare the level of patient satisfaction with the LNG-IUC at the end of the 12 weeks between the 3 study groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuation Rates of the LNG-IUC at the End of the 12 Week Between the 3 Study Groups</measure>
    <time_frame>12 weeks</time_frame>
    <description>To compare continuation rates of the LNG-IUC at the end of the 12 week between the 3 study groups</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Contraception</condition>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>transdermal estradiol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participants will be randomized to transdermal estradiol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oral naproxen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participants will be randomized to oral naproxen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oral placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>participants will be randomized to oral placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>transdermal estradiol</intervention_name>
    <description>transdermal estradiol 0.1mg patch to be changed weekly for 12 weeks.</description>
    <arm_group_label>transdermal estradiol</arm_group_label>
    <other_name>Climara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naproxen</intervention_name>
    <description>naproxen 500mg by mouth twice daily for the first 5 days of every 4 week period for a total of 12 weeks</description>
    <arm_group_label>oral naproxen</arm_group_label>
    <other_name>Naprosyn, Anaprox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral placebo</intervention_name>
    <description>oral placebo to be taken by mouth twice daily for the first 5 days of a 4 week block for a total of 5 weeks</description>
    <arm_group_label>oral placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be of reproductive age from 18 to 45 years

          -  Must be choosing LNG-IUC for contraception

          -  Must be English-speaking

          -  Be willing to avoid additional use of exogenous hormones, such as oral contraceptives,
             for the duration of the study

          -  Be willing to avoid additional use of nonsteroidal antiinflammatory drugs, such as
             ibuprofen or aspirin for the duration of the study

          -  Be willing to comply with the study protocol, keep the bleeding diary and comply with
             follow-up visits and telephone interviews as scheduled

          -  Be willing and able to provide informed consent

        Exclusion Criteria:

          -  Known or suspected pregnancy

          -  Contraindication to estrogen use, such as presence or history of:

               -  venous thromboembolism

               -  Arterial thrombosis

               -  Thrombophilia disorders, or known family history of

               -  Hypertension

               -  Migraine headaches with aura or focal neurologic involvement, or any migraine
                  over age 35 years

          -  Recent or planned future major surgery which will result in prolonged immobilization
             during the study period

          -  Presence or history of severe hepatic disease or liver tumors

          -  Known or suspected estrogen-dependent neoplasm

          -  Vaginal bleeding of unknown etiology

          -  Any cigarette smoking and age over 35 years

          -  Contraindications to nonsteroidal anti-inflammatory use, such as presence or history
             of:

               -  Gastrointestinal ulcer disease

               -  Renal insufficiency or failure

               -  Aspirin-induced asthma or hypersensitivity reaction

               -  Systemic lupus erythematosus (SLE) and mixed connective tissue disorders

               -  Use of anticoagulants

               -  Cardiovascular disease

          -  Use of medications that alter estrogen metabolism, i.e. rifampin, certain anti-seizure
             medications

          -  Regular use of an NSAID

          -  Current diagnosis of menorrhagia, metrorrhagia, symptomatic uterine fibroids, or
             endometrial polyp

          -  Hypersensitivity or allergy to any of the components of the estradiol patch

          -  Use of injectable contraception within 6 months of the start of the study medication

          -  Delivery or abortion in the previous 4 weeks

          -  Prior use of LNG-IUD

          -  Any condition, that in the opinion of the investigator, would contraindicate study
             participation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tessa E Madden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School fo Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2008</study_first_submitted>
  <study_first_submitted_qc>November 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2008</study_first_posted>
  <results_first_submitted>June 27, 2013</results_first_submitted>
  <results_first_submitted_qc>December 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 11, 2014</results_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Tessa Madden, MD</investigator_full_name>
    <investigator_title>Asst. Professor</investigator_title>
  </responsible_party>
  <keyword>contraception</keyword>
  <keyword>progestin contraception</keyword>
  <keyword>intrauterine contraception</keyword>
  <keyword>unscheduled bleeding</keyword>
  <keyword>placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>129 participants were recruited from November 2008 to January 2010 and follow-up was conducted through May 2010.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Oral Naproxen</title>
          <description>participants will be randomized to oral naproxen
naproxen : naproxen 500mg by mouth twice daily for the first 5 days of every 4 week period for a total of 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Oral Placebo</title>
          <description>oral placebo : oral placebo to be taken by mouth twice daily for the first 5 days of a 4 week block for a total of 5 weeks</description>
        </group>
        <group group_id="P3">
          <title>Transdermal Estradiol</title>
          <description>participants will be randomized to transdermal estradiol
transdermal estradiol : transdermal estradiol 0.1mg patch to be changed weekly for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Naproxen</title>
          <description>participants will be randomized to oral naproxen
naproxen : naproxen 500mg by mouth twice daily for the first 5 days of every 4 week period for a total of 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Oral Placebo</title>
          <description>oral placebo : oral placebo to be taken by mouth twice daily for the first 5 days of a 4 week block for a total of 5 weeks</description>
        </group>
        <group group_id="B3">
          <title>Transdermal Estradiol</title>
          <description>participants will be randomized to transdermal estradiol
transdermal estradiol : transdermal estradiol 0.1mg patch to be changed weekly for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="43"/>
            <count group_id="B4" value="129"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="129"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.3" spread="4.7"/>
                    <measurement group_id="B2" value="25" spread="4.2"/>
                    <measurement group_id="B3" value="26.2" spread="5.1"/>
                    <measurement group_id="B4" value="25.8" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="129"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Bleeding and Spotting Days</title>
        <description>The median number of bleeding and spotting days reported at 12 weeks.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Naproxen</title>
            <description>participants will be randomized to oral naproxen
naproxen : naproxen 500mg by mouth twice daily for the first 5 days of every 4 week period for a total of 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>oral placebo : oral placebo to be taken by mouth twice daily for the first 5 days of a 4 week block for a total of 5 weeks</description>
          </group>
          <group group_id="O3">
            <title>Transdermal Estradiol</title>
            <description>participants will be randomized to transdermal estradiol
transdermal estradiol : transdermal estradiol 0.1mg patch to be changed weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Bleeding and Spotting Days</title>
          <description>The median number of bleeding and spotting days reported at 12 weeks.</description>
          <units>DAYS</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" lower_limit="5" upper_limit="83"/>
                    <measurement group_id="O2" value="32" lower_limit="9" upper_limit="84"/>
                    <measurement group_id="O3" value="44" lower_limit="2" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.03</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.02</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Bleeding Days Observed in Women With a LNG-IUC Treated With Naproxen, Estradiol and Placebo.</title>
        <description>Median number of bleeding days observed in women with a LNG-IUC treated with naproxen, estradiol and placebo at 16 weeks.</description>
        <time_frame>16 weeks</time_frame>
        <population>There 129 women who were randomly assigned to the 3 arms. At 12 weeks of follow up, there were 17 participants lost to follow up. This resulted in a total analysis population of 112 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Transdermal Estradiol</title>
            <description>participants will be randomized to transdermal estradiol
transdermal estradiol: transdermal estradiol 0.1mg patch to be changed weekly for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Oral Naproxen</title>
            <description>participants will be randomized to oral naproxen
naproxen: naproxen 500mg by mouth twice daily for the first 5 days of every 4 week period for a total of 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Oral Placebo</title>
            <description>oral placebo: oral placebo to be taken by mouth twice daily for the first 5 days of a 4 week block for a total of 5 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Bleeding Days Observed in Women With a LNG-IUC Treated With Naproxen, Estradiol and Placebo.</title>
          <description>Median number of bleeding days observed in women with a LNG-IUC treated with naproxen, estradiol and placebo at 16 weeks.</description>
          <population>There 129 women who were randomly assigned to the 3 arms. At 12 weeks of follow up, there were 17 participants lost to follow up. This resulted in a total analysis population of 112 participants.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="11" upper_limit="111"/>
                    <measurement group_id="O2" value="53" lower_limit="2" upper_limit="106"/>
                    <measurement group_id="O3" value="38" lower_limit="10" upper_limit="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction With the LNG-IUC at the End of the 12 Weeks Between the 3 Study Groups.</title>
        <description>To compare the level of patient satisfaction with the LNG-IUC at the end of the 12 weeks between the 3 study groups.</description>
        <time_frame>12 weeks</time_frame>
        <population>There 129 women who were randomly assigned to the 3 arms. At 12 weeks of follow up, there were 17 participants lost to follow up. This resulted in a total analysis population of 112 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Naproxen</title>
            <description>participants will be randomized to oral naproxen
naproxen : naproxen 500mg by mouth twice daily for the first 5 days of every 4 week period for a total of 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>oral placebo : oral placebo to be taken by mouth twice daily for the first 5 days of a 4 week block for a total of 5 weeks</description>
          </group>
          <group group_id="O3">
            <title>Transdermal Estradiol</title>
            <description>participants will be randomized to transdermal estradiol
transdermal estradiol : transdermal estradiol 0.1mg patch to be changed weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction With the LNG-IUC at the End of the 12 Weeks Between the 3 Study Groups.</title>
          <description>To compare the level of patient satisfaction with the LNG-IUC at the end of the 12 weeks between the 3 study groups.</description>
          <population>There 129 women who were randomly assigned to the 3 arms. At 12 weeks of follow up, there were 17 participants lost to follow up. This resulted in a total analysis population of 112 participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Satisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Somewhat satisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not satisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Continuation Rates of the LNG-IUC at the End of the 12 Week Between the 3 Study Groups</title>
        <description>To compare continuation rates of the LNG-IUC at the end of the 12 week between the 3 study groups</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Naproxen</title>
            <description>participants will be randomized to oral naproxen
naproxen : naproxen 500mg by mouth twice daily for the first 5 days of every 4 week period for a total of 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo</title>
            <description>oral placebo : oral placebo to be taken by mouth twice daily for the first 5 days of a 4 week block for a total of 5 weeks</description>
          </group>
          <group group_id="O3">
            <title>Transdermal Estradiol</title>
            <description>participants will be randomized to transdermal estradiol
transdermal estradiol : transdermal estradiol 0.1mg patch to be changed weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Continuation Rates of the LNG-IUC at the End of the 12 Week Between the 3 Study Groups</title>
          <description>To compare continuation rates of the LNG-IUC at the end of the 12 week between the 3 study groups</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Oral Naproxen</title>
          <description>participants will be randomized to oral naproxen
naproxen : naproxen 500mg by mouth twice daily for the first 5 days of every 4 week period for a total of 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Oral Placebo</title>
          <description>oral placebo : oral placebo to be taken by mouth twice daily for the first 5 days of a 4 week block for a total of 5 weeks</description>
        </group>
        <group group_id="E3">
          <title>Transdermal Estradiol</title>
          <description>participants will be randomized to transdermal estradiol
transdermal estradiol : transdermal estradiol 0.1mg patch to be changed weekly for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Tessa Madden</name_or_title>
      <organization>Washington University</organization>
      <phone>3147471331</phone>
      <email>maddent@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

